LAUSR

Key Points Question Is restricted mean survival time (RMST) analysis feasible to translate comparative cardiovascular and kidney outcomes of sodium-glucose cotransporter-2 inhibitor (SGLT2i) vs dipeptidyl peptidase-4 inhibitor (DPP4i) therapy in routine clinical settings? Findings In this comparative effectiveness study of 21 144 propensity score–matched pairs of patients with stable SGLT2i and DPP4i use for cardiovascular outcomes and 19 951 matched pairs for kidney outcomes, RMST analysis translated the SGLT2i-associated cardiorenal outcomes into clinical intuitive estimates, and estimated heterogenous treatment effects among patients with diverse characteristics in routine clinical settings. Meaning This study’s findings suggest the feasibility of using RMST analysis to supplement traditional survival analyses for investigating cardiorenal outcomes among diverse patients with SGLT2i treatment.